NBIX analyst estimates
Neurocrine Biosciences (NBIX) analyst ratings, the average price target and its range, and every firm's latest call.
NBIX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 29, 2026 | UBS | Neurocrine price target lowered to $214 from $231 at UBS | $214.00 |
| Sep 11, 2026 | Morgan Stanley | Neurocrine price target raised to $183 from $182 at Morgan Stanley | $183.00 |
| Sep 8, 2026 | RBC Capital | RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers' | $198.00 |
| Aug 13, 2026 | Deutsche Bank | Neurocrine price target lowered to $165 from $190 at Deutsche Bank | $165.00 |
| Aug 13, 2026 | Morgan Stanley | Neurocrine price target lowered to $182 from $196 at Morgan Stanley | $182.00 |
| Aug 13, 2026 | Bernstein | Neurocrine price target lowered to $218 from $221 at Bernstein | $218.00 |
| Aug 3, 2026 | Canaccord Genuity | Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord | $210.00 |
| Aug 3, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX) | $215.00 |
| Aug 3, 2026 | Wedbush | Neurocrine price target raised to $194 from $185 at Wedbush | $194.00 |
| Jul 31, 2026 | Guggenheim | Neurocrine price target raised to $222 from $200 at Guggenheim | $222.00 |
| Jul 31, 2026 | Robert W. Baird | Neurocrine price target raised to $225 from $186 at Baird | $225.00 |
| Jul 31, 2026 | Piper Sandler | Neurocrine price target raised to $210 from $207 at Piper Sandler | $210.00 |
| Jul 31, 2026 | Needham | Neurocrine price target raised to $204 from $200 at Needham | $204.00 |
| Jul 31, 2026 | Deutsche Bank | Neurocrine price target raised to $190 from $170 at Deutsche Bank | $190.00 |
| Jul 31, 2026 | Morgan Stanley | Neurocrine price target raised to $196 from $193 at Morgan Stanley | $196.00 |
- 22 firms rate NBIX: 19 buy, 3 hold, 0 sell.
- The average price target is $204.83 from 12 analysts, from $165.00 to $225.00.
Updated 2026-11-03 00:46 UTC